3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Renal Cell
32
Sarcoma
29
Neoplasm Metastasis
17
Ovarian Neoplasms
10
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Neoplasms
6
Kidney Neoplasms
6
Recurrence
5
Lung Neoplasms
5
Liposarcoma
5
Thyroid Neoplasms
4
Melanoma
4
Leiomyosarcoma
4
Hemangiosarcoma
4
Urinary Bladder Neoplasms
3
Solid Tumors
3
Pancreatic Neoplasms
3
Neurofibrosarcoma
3
Glioblastoma
3
Gastrointestinal Stromal Tumors
3
Chondrosarcoma, Extraskeletal Myxoid
3
Advanced Cancers
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solitary Fibrous Tumors
2
Small Cell Lung Carcinoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdomyosarcoma
2
Interventions
Paclitaxel
42
Carboplatin
35
pembrolizumab
25
Surveys and Questionnaires
23
Letrozole
15
Radiotherapy
14
Megestrol Acetate
14
Blood Specimen Collection
14
Bevacizumab
13
olaparib
12
Metformin
12
dostarlimab
10
Indocyanine Green
10
durvalumab
9
Observation
9
Medroxyprogesterone Acetate
9
Cisplatin
9
lenvatinib
8
atezolizumab
8
Magnetic Resonance Spectroscopy
8
Everolimus
8
Early Intervention, Educational
8
Counseling
8
niraparib
7
Specimen Handling
7
Sentinel Lymph Node Biopsy
7
Radiation
7
Methods
7
Lymph Node Excision
7
Hysterectomy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Endometrial Neoplasms
×
pazopanib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled